Prospective, Randomized, Double-blind, Placebo-controlled Clinical Study of the Safety and Efficacy of the Vaccine for the Prevention of Pentavalent Live Rotavirus Infection in Healthy Subjects (Target Age of 18-45 Years Old).

Limited Liability Company Pharm Aid1 site in 1 country40 target enrollmentJune 25, 2018

ConditionsRotavirus Infections Rotavirus Vaccines

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Rotavirus Infections
Sponsor: Limited Liability Company Pharm Aid
Enrollment: 40
Locations: 1
Primary Endpoint: Geometric Mean Titer (GMT) of antibody
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the presented study was to evaluate the safety and immunological efficacy in preventing the rotavirus infection within a cohort of healthy subjects (target age of 18-45 years old) by using the pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried).

Detailed Description

The clinical study named "Prospective, randomized, double-blind, placebo-controlled study of safety and immunological efficacy for preventing a rotavirus infection pentavalent vaccine, live attenuated at the healthy subjects at the age of 18-45 years" was conducted in the Russian Federation. The mentioned study was performed as per Protocol of clinical trial No. RTB 001/18 (given by MOH RF exp June 7, 2018). All relevant requirements of the National Legislative system and the international rules of conduct of clinical trials (ICH GCP). The study objective was to assess the safety and immunological efficacy for preventing a rotavirus infection pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried) at healthy adults aged 18 to 45 years for the subsequent vaccination of the children's contingent. For the achievement of a goal, it was necessary to solve the following problems: 1. Assessment of the vaccine's safety for preventing a rotavirus infection pentavalent live compared to placebo at a single oral introduction to volunteers at the age of 18-45 years. 2. Immunological efficacy assessment for prevention of a rotavirus infection pentavalent live in comparison with placebo at a single oral introduction to volunteers at the age of 18-45 years

Registry

clinicaltrials.gov

Start Date

June 25, 2018

End Date

July 27, 2018

Last Updated

4 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Limited Liability Company Pharm Aid

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The signed informed consent;
•Healthy participants, men's and females aged from 18 up to 45 years inclusive;
•Readiness of participants and their sexual partners to use reliable methods of contraception (a combination of at least two modes, including one barrier method, for example, use of a spermicide and condom) from the moment of signing of the informed consent (that is in 3 days before administration of drugs) and before the expiration of 1 month after completion of participation in the study;
•The verified diagnosis "is healthy," established according to collecting the anamnesis and physical inspection:
•absence in the anamnesis and at the time of screening clinically significant dysfunctions cardiovascular, respiratory, nervous, hemopoietic, endocrine, gastrointestinal systems, liver, and kidneys;
•absence of persistent infections (HIV, hepatitis B, C, syphilis);
•absence within 30 days before inclusion in the study of sharp, infectious diseases;
•absence of the mental disorders and any other states capable to affectability of the participant to follow requirements of the protocol;
•lack of complaints to the state of health within 30 days before inclusion in the study;
•hemodynamic indicators within norm: systolic arterial blood pressure - within 100 - 130 mm Hg., diastolic arterial blood pressure - within 60 - 90 mm Hg;

Exclusion Criteria

•The severe vaccine-challenged reactions/complications connected with the previous vaccination;
•Allergic reactions to components of vaccine or any previous vaccination;
•Any carried-out vaccination less than in 2 months before the present study;
•In the chronic anamnesis diseases of the digestive tract, causes intestinal invagination, gastrointestinal pathology, surgical interventions on abdominal organs;
•Clinically significant deviations of laboratory and tool indicators (including standard pathological changes on the ECG) overstepping the bounds of the range of normal values revealed on screening and capable of negatively impacting the safety of participants of the volunteer in the study;
•Any diseases within four weeks preceding screening;
•Presence of any oncological diseases (including in the anamnesis);
•Any disease demands continuous therapy, including vegetable drugs or the expected concurrent therapy during the study;
•Donor blood donation (450 ml of blood or plasma and more) or loss of 500 or more ml of blood in 3 months before the study;
•Positive analysis on HIV, Hepatitis B and C, and syphilis (RW);